Tight interactions between WNT/β-catenin with different cells within tumor immune ecosystem, close interactions with PD-1/PD-L1 axis, and the promising outcomes from clinical trials targeting the two are all indicative of the application of combination therapies using WNT/β-catenin inhibitors with anti-PD-(L)1 in cancer immunotherapy, particularly in tumors with cold immunity and highly aggressive profile. Here, CD274 is linked to neoplasm.